Safety and Pharmacokinetics of Standardized Extract of Centella asiatica (ECa 233) Capsules in Healthy Thai Volunteers: A Phase 1 Clinical Study

Abstract

The aim of this study was to investigate the safety and pharmacokinetic profiles of a newly developed, standardized extract of Centella asiatica (ECa 233) capsule in healthy Thai volunteers. This study was designed as an open-labeled, 2-sequence dosage, single- and repeated-dose study investigated under fasting conditions. Plasma concentrations of the parent compounds and their relative acid metabolites were measured and pharmacokinetic parameters were calculated using noncompartmental analysis. Tolerability was assessed based on physical examinations, monitoring of vital signs, clinical laboratory tests, and any observed adverse events. A key finding of this study was that the pharmacokinetics of ECa 233 in healthy volunteers did not correspond with its pharmacokinetics in animal studies. As indicated in human pharmacokinetic parameters, maximum plasma concentration and area under the curve of the parent compounds (madecassoside and asiaticoside) were very low, while their respective metabolites (madecassic acid and asiatic acid) demonstrated higher values. Based on the pharmacokinetic results observed in the dose comparison, accumulation of active metabolites after repeated dose is highly suggestive. In addition, the asiatic acid profile showed 2-fold increase in C_max and AUC_(0–t) after increasing dose from 250 to 500 mg of ECa 233. Lastly, the safety and tolerability evaluation illustrated that single and multiple doses in both 250 and 500 mg oral administration of ECa 233 were well tolerated, and none of the volunteers discontinued their participation due to adverse effects during the study.

Key words

Centella asiatica - Apiaceae, pharmacokinetics - madecassic acid - asiatic acid - triterpenoid glycosides

• References

• 1 Kelley BJ, Petersen RC. Alzheimerʼs disease and mild cognitive impairment. Neurol Clin 2007; 25: 577
• 2 Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2012; 2: a006148
• 3 Webster SJ, Bachstetter AD, Nelson PT, Schmitt FA, Van Eldik LJ. Using mice to model Alzheimerʼs dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. Front Genet 2014; 5: 88
• 4 Orhan IE. Centella asiatica (L.) Urban: from traditional medicine to modern medicine with neuroprotective potential. Evid Based Complement Alternat Med 2012; 2012: 946259
• 5 Singh RH, Narsimhamurthy K, Singh G. Neuronutrient impact of Ayurvedic Rasayana therapy in brain aging. Biogerontology 2008; 9: 369-374
• 6 Veerendra Kumar MH, Gupta YK. Effect of different extracts of Centella asiatica on cognition and markers of oxidative stress in rats. J Ethnopharmacol 2002; 79: 253-260
• 7 Soumyanath A, Zhong YP, Henson E, Wadsworth T, Bishop J, Gold BG, Quinn JF. Centella asiatica extract improves behavioral deficits in a mouse model of Alzheimerʼs disease: investigation of a possible mechanism of action. Int J Alzheimers Dis 2012; 2012: 381974
• 8 Saifah E, Suttisri R, Patarapanich C, Laungchonlatan S, Tantisira MH, Tantisira B. Preparation methods of colorless mixture between madecassoside and asiaticoside from Centella asiatica . In: Department of Intellectual Property MoC. ed. C07H 1/00 ed. Bangkok, Thailand: Chulalongkorn University; 2009
• 9 Tantisira MH. Research and development of standardized extract of Centella asiatica ECa 233. The International Conference on Herbal and Traditional Medicine KhonKaen, Thailand; 2015
• 10 Tantisira MH, Tantisira B, Patarapanich C, Suttisri R, Luangcholatan S, Mingmalailak S, Wanasuntronwong A, Saifah E. Effect of a standardized extract of Centella asiatica ECa 233 on learning and memory impairment induced by transient bilateral common carotid artery occlusion in mice. Thai J Pharmacol 2010; 32: 22-33
• 11 Kam-eg A, Tantisira B, Tantisira MH. Preliminary study on effects of standardized extract of Centella asiatica, Eca 233 on deficit of learning and memory induced by an intracerebroventricular injection of β-amyloid peptide in mice. Thai J Pharmacol 2009; 33: 79-82
• 12 Chivapat S, Chavalittumrong P, Tantisira MH. Acute and sub-chronic toxicity studies of a standardized extract of Centella asiatica ECa 233. Thai J Pharm Sci 2011; 35: 55-64
• 13 Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P. Pharmacokinetics of a standardized extract of Centella asiatica ECa 233 in rats. Planta Med 2017; 83: 710-717
• 14 Rush WR, Murray GR, Graham DJ. The comparative steady-state bioavailability of the active ingredients of madecassol. Eur J Drug Metab Pharmacokinet 1993; 18: 323-326
• 15 Hengjumrut P, Anukunwithaya T, Tantisira MH, Tantisira B, Khemawoot P. Comparative pharmacokinetics between madecassoside and asiaticoside presented in a standardised extract of Centella asiatica, ECa 233 and their respective pure compound given separately in rats. Xenobiotica 2018; 48: 18-27
• 16 US Food and Drug Administration (USFDA). Guidance for industry. Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Available at: https://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf Accessed September 23, 2017
• 17 Leng DD, Han WJ, Rui Y, Dai Y, Xia YF. In vivo disposition and metabolism of madecassoside, a major bioactive constituent in Centella asiatica (L.) Urb. J Ethnopharmacol 2013; 150: 601-608
• 18 Kobashi K, Akao T. Relation of intestinal bacteria to pharmacological effects of glycosides. Biosci Microflora 1997; 16: 1-7
• 19 Bone K, Mills S. Principles and Practice of Phytotherapy: Modern herbal Medicine. 2nd ed.. Saint Louis: Churchill Livingstone; 2013
• 20 Cheng Q, Liao M, Hu H, Li H, Wu L. Asiatic acid (AA) sensitizes multidrug-resistant human lung adenocarcinoma A549/DDP cells to cisplatin (DDP) via down regulation of p-glycoprotein (MDR1) and its targets. Cell Physiol Biochem 2018; 47: 279-292
• 21 Mook-Jung I, Shin JE, Yun SH, Huh K, Koh JY, Park HK, Jew SS, Jung MW. Protective effects of asiaticoside derivatives against beta-amyloid neurotoxicity. J Neurosci Res 1999; 58: 417-425
• 22 Krishnamurthy RG, Senut MC, Zemke D, Min J, Frenkel MB, Greenberg EJ, Yu SW, Ahn N, Goudreau J, Kassab M, Panickar KS, Majid A. Asiatic acid, a pentacyclic triterpene from Centella asiatica, is neuroprotective in a mouse model of focal cerebral ischemia. J Neurosci Res 2009; 87: 2541-2550
• 23 Meeran MF, Goyal SN, Suchal K, Sharma C, Patil CR, Ojha SK. Pharmacological properties, molecular mechanisms, and pharmaceutical development of asiatic acid: a pentacyclic triterpenoid of therapeutic promise. Front Pharmacol 2018; 9: 892
• 24 Hackshaw A. A concise Guide to clinical Trials. Hoboken: John Wiley & Sons; 2011
• 25 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: text and methodology Q2 (R1). Available at: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf Accessed January 8, 2018